Personalized treatment tool

A computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus, said method comprising the steps of:

• (a) receiving glucose data of said individual at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said individual, and/or at least three matched pre-prandial glucose measurement values and post-prandial glucose measurement values from said Individual,
• (b) establishing from a memory one or more of
• (b1) a fasting glucose threshold value,
• (b2) a post-prandial glucose threshold value,
• (b3) a hypoglycemia threshold, and
• (b4) a maximal number of hypoglycemic events to be tolerated,
• (c) carrying out by the processing unit an analysis of the individual's glucose measurements values, said analysis comprising one or more of:
• (c1) determining a first statistical parameter indicative for the deviation between the at least three fasting glucose measurement values and the fasting glucose threshold value,
• (c2) determining a second statistical parameter indicative for the deviation between the the at least three post-prandial glucose measurement values and the post-prandial glucose threshold value,
• (c3) determining a Hyperglycemia Prevalence Index (HPI) or a value derived therefrom, wherein the HPI is the ratio of the first statistical parameter as determined in step (c1) to the second statistical parameter as determined in step (c2),
• (c4) determining the number of hypoglycemic events by comparing the individual's fasting glucose measurement values, pre-prandial glucose measurement values and post-prandial glucose measurement values to the hypoglycemia threshold, and
• (d) aiding in the guidance of diabetes drug therapy of said individual, wherein said aiding is carried out by the processor unit and is based on the result(s) of the analysis carried out in step c), and on one or more of the following
• (d1) the effects of at least ten different diabetes drugs on fasting glucose,
• (d2) the effects of the at least ten different diabetes drugs on postprandial glucose,
• (d3) the Hyperglycemia Efficacy Indices of the at least ten drugs, wherein the Hyperglycemia Efficacy Index (HEI) for a drug is the ratio of the effect of said drug on fasting glucose to the effect of said drug on the post-prandial glucose,
• (d4) the risks of causing hypoglycemia of the at least ten diabetes drugs,
• wherein the effects under (d1), (d2), the indices under (d3) and the risks under (d4) are established from a database for said at least ten diabetes drugs from a memory,
• wherein the first and/or second statistical parameter(s) in steps (c1) and/or (c2) being larger than a respective predefined maximum for the first and/or second statistical parameter indicative for a deviation to be tolerated which is established from the memory is indicative for the need to correct hyperglycemia in said individual,
• wherein a number of hypoglycemic events as determined in step (c4) which is larger than a predefined maximal number of hypoglycemic events to be tolerated by the individual which is established from the memory is indicative for the need to avoid hypoglycemia, and
• wherein the aid in the guidance comprises the recommendation to change the current diabetes drug therapy if the analysis in step c) indicates that there is a need to avoid hypoglycemia and/or to correct hyperglycemia in said individual, wherein the current diabetes drug is one of the at least ten different diabetes drugs, the processing unit further carries out a comparison of the Hyperglycemia Efficacy Index (HEI) of the current diabetes drug and the HEI value of the remaining drugs established from the database of the memory, and a recommended alternative drug for replacement has the most similar HEI value as the current administered drug;
• or
• wherein the aid in the guidance comprises the recommendation to add a further diabetes drug to the therapy if the analysis in step c) indicates that there is a need to correct hyperglycemia, wherein the addition of a diabetes drug out of said at least ten diabetes drugs is recommended which has a HEI value which has the smallest difference to the value of the individual's HPI or the value derived therefrom determined in step (c3).